Su Shiqiang, Liu Lizhe, Li Chao, Zhang Jin, Li Shen
Department of Urology, Shijiazhuang People's Hospital, The No.1 Hospital of Shijiazhuang, Shijiazhuang, China.
Department of Pathophysiology, Hebei Medical University, Shijiazhuang, China.
Front Oncol. 2020 Sep 4;10:1650. doi: 10.3389/fonc.2020.01650. eCollection 2020.
To examine the potential prognostic significance of pretreatment De Ritis ratio (aspartate transaminase/alanine transaminase ratio) in urological cancers, including upper tract urothelial cancer (UTUC), renal cell carcinoma (RCC), prostate cancer (PCa), bladder cancer (BCa). Potential literatures were searched with PubMed, Embase, Cochrane Library, and Web of Science in December 2019. Merged hazard ratios (HRs) and 95% confidence intervals (CIs) were used to evaluate the associations. Totally, 15 studies with 8,565 patients were included. Merged results showed that an elevated pretreatment De Ritis ratio was correlated with poorer OS (HR 1.80, 95% CI 1.61-2.01), CSS (HR 2.15, 95% CI 1.80-2.56), PFS (HR 1.57, 95% CI 1.34-1.85), BRFS (HR 1.67, 95% CI 1.11-2.53) for urological cancers. Subgroup analyses by cancer type for OS found that De Ritis ratio can be a predictor in UTUC (HR 1.91, 95% CI 1.57-2.33), RCC (HR 1.74, 95% CI 1.47-2.07), and BCa (HR 1.80, 95% CI 1.43-2.27). Similar results could be found for CSS (UTUC: HR 2.46, 95% CI 1.93-3.13; RCC: HR 1.90, 95% CI 1.46-2.47; BCa: HR 2.71, 95% CI 1.39-5.31) and PFS (UTUC: HR 1.59, 95% CI 1.15-2.20; RCC: HR 1.52, 95% CI 1.26-1.83; BCa: HR 1.79, 95% CI 1.18-2.72). There was no publication bias among these included studies. Pretreatment De Ritis ratio was a significant predictor for OS, CSS, PFS and BRFS in urological cancers, indicating that it could be a promising prognostic factor during clinical practice.
为研究治疗前德瑞蒂斯比值（天冬氨酸转氨酶/丙氨酸转氨酶比值）在包括上尿路尿路上皮癌（UTUC）、肾细胞癌（RCC）、前列腺癌（PCa）、膀胱癌（BCa）在内的泌尿系统癌症中的潜在预后意义。2019年12月，通过PubMed、Embase、Cochrane图书馆和Web of Science检索相关文献。采用合并风险比（HRs）和95%置信区间（CIs）评估相关性。共纳入15项研究，涉及8565例患者。合并结果显示，治疗前德瑞蒂斯比值升高与泌尿系统癌症患者较差的总生存期（OS，HR 1.80，95% CI 1.61 - 2.01）、癌症特异性生存期（CSS，HR 2.15，95% CI 1.80 - 2.56）、无进展生存期（PFS，HR 1.57，95% CI 1.34 - 1.85）、乳腺癌无复发生存期（BRFS，HR 1.67，95% CI 1.11 - 2.53）相关。按癌症类型对OS进行亚组分析发现，德瑞蒂斯比值可作为UTUC（HR 1.91，95% CI 1.57 - 2.33）、RCC（HR 1.74，95% CI 1.47 - 2.07）和BCa（HR 1.80，95% CI 1.43 - 2.27）的预测指标。CSS（UTUC：HR 2.46，95% CI 1.93 - 3.13；RCC：HR 1.90，95% CI 1.46 - 2.47；BCa：HR 2.71，95% CI 1.39 - 5.31）和PFS（UTUC：HR 1.59，95% CI
